In the latest session, Aldeyra Therapeutics Inc (NASDAQ: ALDX) closed at $4.25 down -3.41% from its previous closing price of $4.40. On the day, 577477 shares were traded.
Ratios:
For a deeper understanding of Aldeyra Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.44 and its Current Ratio is at 6.44. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 05 ’24 when PERCEPTIVE ADVISORS LLC bought 37,712 shares for $4.74 per share. The transaction valued at 178,755 led to the insider holds 9,275,851 shares of the business.
PERCEPTIVE ADVISORS LLC bought 140,281 shares of ALDX for $655,112 on Apr 04 ’24. The 10% Owner now owns 9,238,139 shares after completing the transaction at $4.67 per share. On Apr 03 ’24, another insider, PERCEPTIVE ADVISORS LLC, who serves as the 10% Owner of the company, bought 309,847 shares for $4.09 each. As a result, the insider paid 1,267,274 and bolstered with 9,097,858 shares of the company.
Stock Price History:
Over the past 52 weeks, ALDX has reached a high of $11.97, while it has fallen to a 52-week low of $1.42.
Shares Statistics:
A total of 59.20M shares are outstanding, with a floating share count of 56.55M. Insiders hold about 3.98% of the company’s shares, while institutions hold 61.22% stake in the company.
Earnings Estimates
There are USCF Gold Strategy Plus Income different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $7.06, with high estimates of $11.64 and low estimates of $39.25.
Analysts are recommending an EPS of between $Technology and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
